Updated results from the CheckMate 274 trial support the use of adjuvant nivolumab as standard care for high-risk muscle-invasive urothelial carcinoma, according to researchers.
Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse ...
First-of-its-kind research looking at survival rates for patients with incurable larynx cancer has been published.
Craig A Clifford, DVM, MS, DACVIM (Oncology) talks about the most common bladder tumor in dogs, misdiagnosis, and the Cadet ...
Neoadjuvant therapy for high-risk renal cell carcinoma (RCC) may offer a survival advantage over adjuvant therapy, according to data presented at the 2024 annual meeting of the Society of Urologic ...
A recent study has shed light on improving the prognostication of Merkel cell carcinoma, a rare and aggressive form of skin ...
Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 ...
Findings seen in patients with microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback